| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.42 | 0.04 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.04 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.45 | 0.04 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.05 |